Impact of Oxidized Low Density Lipoprotein Cholesterol under Ezetimibe or Rosuvastatin Therapy on Endothelial Function

Results: At baseline, MDA-LDL was inversely correlated with FMD (r=-0.565, p<0.05). MDA-LDL and FMD were improved in both groups (MDA-LDL: E; pre 155.7±73.8mg/dl, post 120.6±46.4mg/dl, p<0.05, R; pre 148.7±48.2mg/dl, post 104.2±28.9mg/dl, p<0.05), (FMD: E; pre 4.9±3.1%, post 7.6±2.5%, p<0.05, R; pre 4.3±1.8%, post 7.6±3.0%, p<0.01). Although the improvement of LDL was better in rosuvastatin group, variation of MDALDL and FMD were not different between the groups (MDA-LDL: E; 35.1±41.1mg/dl vs R; 44.4±52.8mg/dl, ns, FMD: E; 2.6±3.0% vs R; 3.3±2.3%, ns). The improvement of FMD was correlated with variation of MDA-LDL (r= 0.586, p< 0.01).